| Literature DB >> 32219081 |
Sebastiano Guarnaccia1, Cristina Quecchia2, Andrea Festa3, Michele Magoni4, Elena Zanardini5, Valentina Brivio5, Carmelo Scarcella4, Valeria Gretter2, Cinzia Gasparotti4, Malica Frassine2, Martina Ferrari1, Rosa Maria Limina6, Raffaele Spiazzi7, Raffaele Badolato1, Francesco Donato3.
Abstract
Background: Limited evidence exists for the effectiveness of educational programs that improve pediatric asthma control in real-world settings. We aimed to assess the impact of a diagnostic, therapeutic, and educational pathway (DTEP) for asthma management in children and adolescents attending an asthma referral center.Entities:
Keywords: GINA guideline adherence; asthma; asthma management; children and adolescents; clinical educational pathway; real-life research
Year: 2020 PMID: 32219081 PMCID: PMC7078232 DOI: 10.3389/fped.2020.00039
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Figure 1The two study times considered for computing incidence rates of health outcomes in patients attending (intervention group) or not attending (control group) a diagnostic, therapeutic, and educational pathway (DTEP): time before and after DTEP (left side) for the intervention group, and “early” and a “late” time since asthma diagnosis for the control group (right side).
Incident rates (IRs), percentage difference between after and before following a diagnostic, therapeutic, and educational pathway (DTEP) and between late and early time since asthma diagnosis, in the intervention and control groups, respectively, and incidence rate ratios (IRRs) for hospitalizations, emergency room visits, outpatient services, and drug prescriptions.
| Hospitalization | 54 | 53.4 | 51 | 17.2 (11.2–23.2) | −67.8 | 824 | 52.3 | 443 | 16.7 | −68.1 (64.2 to 71.7) | 0.88 (0.56–1.39) | >0.1 |
| Emergency room visit | 116 | 138.6 | 181 | 67.5 | −51.3 | 425 | 60.3 | 1,355 | 43.3 | −28.2 | 0.61 | 0.001 |
| Outpatient service | 258 | 308.4 (263.6–353.1) | 753 | 280.8 | −8.9 | 1,734 | 246.8 | 5,314 | 169.7 | −31.3 | 1.79 | < 0.001 |
| Drug prescription | 7,873 | 7,846.1 | 12,911 | 4,488.1 | −42.8 | 68,055 | 8,011.3 | 153,544 | 4,537.5 | −43.4 | 0.97 | 0.51 |
The incidence rate ratios for the intervention compared to the control group corresponded to the interaction term between the group and time since asthma diagnosis (before/after DTEP or early/late time) fitting a Poisson regression model for repeated measures including age, gender, and main effects for time and group.
Incident rates (IRs) and incidence rate ratios (IRRs) for use of main pharmacologic classes for asthma treatment.
| LABA plus glucocorticoid | 577 | 575 | 689 | 239.5 | 6,088 | 716.7 | 20,785 | 614.2 | 0.49 (0.43–0.54) | < 0.001 |
| Salbutamol | 1,538 | 1,532.8 | 2,951 | 1,025.8 | 11,776 | 1,386.2 | 27,593 | 815.4 | 1.14 (1.07–1.21) | < 0.001 |
| Inhaled corticosteroids | 1,595 | 1,589.5 | 2,571 | 1,181.7 | 14,466 | 1,702.9 | 22,980 | 679.1 | 1.70 (1.60–1.81) | < 0.001 |
| Leukotriene receptor antagonist | 487 | 485.3 | 677 | 235.3 | 7,687 | 904.9 | 19,886 | 587.7 | 0.75 (0.66–0.84) | < 0.001 |
| Systemic steroids | 418 | 416.6 | 617 | 214.5 | 3,628 | 427.1 | 7,358 | 217.4 | 1.01 (0.89–1.15) | 0.866 |
| Antibiotics | 3,258 | 3,246.9 | 4,872 | 1,693.6 | 24,410 | 2,873.5 | 54,942 | 1,623.6 | 0.92 (0.88–0.97) | 0.001 |
The IRRs for the intervention compared to the control group corresponded to the interaction term between the group and time since asthma diagnosis (before/after DTEP or early/late time) fitting a Poisson regression model for repeated measures including age, gender and main effects for time and group.